Wall Street

Online Stock Market Trading By Freddie Mooche - Senior Financial ColumnistBoston Scientific moves to phase II development of a new MRI imaging technology that coats pacemakers following its recent win in federal court to protect its stent coating technology.

Game details Screenshots Overview Rainbow operatives take to the chaotic streets of Las Vegas as an escalating terrorist siege in "Sin City" threatens to take world terrorism to new, uncontrollable heights. The future of global security hangs in the balance as you battle to defend classic Vegas locations and environments like Fremont Street, the Strip, and casinos. generation technology as you work against the clock to keep one of the world's most recognizable cities from utter devastation.

Stock Investing Course Visit our AXcess News Forum and add your comments on this story. Try your hand at writing, the best story will be published on our news network. Take our health poll too!

While we appreciate the sculpture for its artistic contribution to the Boston skyline, it’s also a scientific instrument useful for boaters.

Stock Market Game Print This Page

The Charlesmark Hotel is located in the Back Bay area of Boston, Mass., across the street from the historic Boston Public Library.

Stock Investing Game June 1, 2004 (AXcess News) Natick MA - After Friday's news that Boston Scientific (NYSE: BSX) won out in its battle to protect its patented stent coating technology from competitor, Cordis Corp, a subsidiary of Johnson & Johnson (NYSE: JNJ), a new coating technology that protects pacemakers from MRI imaging damage was moved to phase II development.

Get the stylish device that frees your phone service, as featured in USATODAY.com, the Wall Street Journal, the New York Times, and FoxTV !

Journal Prime Rate Street Wall Biophan Technologies, Inc. (OTCBB: BIPH) released news Friday citing its phase II agreement with Boston Scientific becoming effective. The agreement calls for the continued research and development of Biophan's MRI safe and image compatible technologies with a variety of Boston Scientific products.

And he defends “Biblical literalism” as an important driver of productive science, not as a barrier to scientific research.

Stock Market News Michael Weiner, CEO of Biophan, said, "We are extremely pleased to be aligned with a company the size of, and with the marketing strength of Boston Scientific."Boston Scientific would not comment on its relationship with Biophan, appearing to be more guarded about its developing biomedical technologies following its recent court battle.Biophan, which holds nine biomedical device patents, awaits the approval on forty-five more.The micro cap company may have gotten a boost in its research and development program with Boston Scientific following the acquisition of TE-Bio, LLC, announced May 15.

Stock Investing Basics TE-Bio holds a patent on a new battery that can extend the lifeAdvertisement

Stock Investing Software of pacemakers and other implantable devices by up to five times its current life, virtually eliminating the need for costly follow up operations to replace those devices power supplies.

Stock Market Trading While Biophan extended its right to license its MRI technology to Boston Scientific under its phase II research and development agreement, the addition of a new, long-life power supply could accelerate Biophan's involvement with Boston Scientific if the no. 1 medical device manufacturing and marketing company moves to incorporate Biophan's latest technology into its applicable products.

Stock Investing For Dummy Patents themselves are the life blood of the biomedical device industry, which are defended vigorously by their respective owners. Cordis Corporation had sued Boston Scientific claiming the Natick, MA-based company had infringed its stent patent. Cordis was seeking a preliminary injunction against Boston Scientific's TAXUS drug-eluting stent in a patent case set for June 2005.Boston Scientific launched its Taxus stent, which is coated with the drug paclitaxel, in the United States on March 4. The company estimates it has more than 70 percent of the market and garnered worldwide sales of $205 million in April.

Stock Market Crash Johnson & Johnson's Cypher was the first drug coated stent on the market with its introduction in April 2003.But Guidant Corp. (NYSE: GDT) is also trying to bring its drug-coated stent to market and is awaiting FDA approval, fueling a prolonged war over market share.Outside of its "stent war", Boston Scientific's showing greater interest in Biophan's biomedical technology might be the best play for its shareholders, though analysts already peg both companies as good investments.Smith Barney Citigroup began coverage on Boston Scientific May 19th, taking a "hold" status on its shares. In April, CSFB began coverage with a "outperform" rating. For Biophan, Cohen Independent Research Group issued a fifty-five page report May 26, pegging the Rochester NY-based company's stock at $4.46 as a low target and $10.59 as a high.

Stock Investing Tip AXcess News will be reporting on any new market trends related to this story. Members should watch their in-box for late breaking news. If you're not a member, consider joining now. Members get the latest business news, commentaries and stock picks delivered right to their in-box.

[ Comment, Edit or Article Submission ]